Alkermes (ALKS) shares declined 6.2% on Friday following Wells Fargo's price target reduction from $42 to $37, though the firm maintained an "Overweight" rating. This market reaction occurred despite the biopharmaceutical company recently reporting strong Q3 earnings, beating analyst estimates with $0.49 EPS and $394.19 million in revenue, and providing optimistic FY25 EPS guidance. While analyst sentiment is mixed, the consensus remains a "Moderate Buy" with an average target price of $44.31, and institutional investors have significantly increased their holdings, now owning over 95% of the stock.
Alkermes plc (NASDAQ:ALKS) shares declined 6.2% on Friday to $29.0780, driven primarily by Wells Fargo & Company lowering its price target from $42.00 to $37.00, despite maintaining an "overweight" rating. This movement was accompanied by an 18% increase in trading volume, signaling a notable market response to the revised analyst sentiment. This immediate market reaction contrasts with Alkermes' robust Q3 financial performance, where the company reported $0.49 EPS, beating the $0.41 consensus by $0.08, and revenue of $394.19 million, exceeding estimates by nearly $39 million. Quarterly revenue also grew 4.3% year-over-year, supported by a net margin of 22.27% and a strong return on equity of 21.81%. The company's positive operational momentum is further underscored by its FY25 EPS guidance of $1.36-$1.47. Despite Wells Fargo's adjustment, the broader analyst consensus remains a "Moderate Buy" with an average target price of $44.31. Institutional investors hold 95.21% of ALKS, with significant recent stake increases by firms like JPMorgan Chase & Co. and American Century Companies Inc., indicating strong long-term conviction.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
